Neoadjuvant chemoradiation versus adjuvant chemotherapy for locally advanced adenocarcinoma of the rectosigmoid junction

  • A C Salami
  • , T Obaid
  • , N J Nweze
  • , M Deleon
  • , L Force
  • , E Gorgun
  • , S Wexner
  • , A R T Joshi

Research output: Contribution to journalArticlepeer-review

4 Scopus citations

Abstract

AIM: The optimal treatment approach for adenocarcinoma of the rectosigmoid junction remains unclear. The aim of this work was to compare outcomes of neoadjuvant chemoradiation (NCR) and adjuvant chemotherapy (AC) treatment for cancer of the rectosigmoid junction.

METHOD: This was a nationwide, retrospective cohort study (2004-2015) using hospital-based cancer outcomes data (National Cancer Database). All patients who underwent resection with curative intent for locally advanced [American Joint Committee on Cancer (AJCC) Stages II and III] adenocarcinoma of the rectosigmoid junction were included. Exclusion criteria were age less than 18 or over 75 years, Charlson-Deyo score > 2, AJCC Stages I and IV and unstaged tumours. Treatment with NCR was compared with treatment with AC, the primary outcome being overall survival. Other end-points were resection margin status, the presence of lymphovascular invasion and postoperative length of stay.

RESULTS: A total of 2828 patients were included in this study, of whom 1701 (59.7%) received NCR. NCR was more frequently utilized in patients who were black (10.3% vs 7.6%, P < 0.05) and underwent treatment at academic institutions (37.9% vs 22.5%, P < 0.05). Treatment with NCR did not differentially influence survival following risk adjustment (hazard ratio 1.17, CI 0.98-1.40; P = 0.085). NCR was independently associated with a decreased likelihood of a positive resection margin (OR 0.44, CI 0.33-0.58; P < 0.001) and lymphovascular invasion (OR 0.51, CI 0.40-0.67; P < 0.001). However, treatment with NCR was associated with the need for prolonged hospitalization compared with AC (7.3 days vs 6.5 days; P = 0.015). The study was limited by its retrospective design, external validity and risk of tumour misclassification.

CONCLUSION: NCR currently seems to be favoured over AC for the management of locally advanced adenocarcinoma of the rectosigmoid junction. This approach may not be justified as NCR is associated with prolonged hospitalization needs without a clear survival benefit when compared with AC. Prospective studies are warranted to definitively compare outcomes of NCR and AC in this patient population.

Original languageEnglish (US)
Pages (from-to)513-520
Number of pages8
JournalColorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
Volume22
Issue number5
DOIs
StatePublished - May 2020
Externally publishedYes

Bibliographical note

Colorectal Disease © 2019 The Association of Coloproctology of Great Britain and Ireland.

Keywords

  • Adenocarcinoma/pathology
  • Chemoradiotherapy
  • Chemotherapy, Adjuvant
  • Humans
  • Infant, Newborn
  • Neoadjuvant Therapy
  • Neoplasm Staging
  • Retrospective Studies

PubMed: MeSH publication types

  • Journal Article

Fingerprint

Dive into the research topics of 'Neoadjuvant chemoradiation versus adjuvant chemotherapy for locally advanced adenocarcinoma of the rectosigmoid junction'. Together they form a unique fingerprint.

Cite this